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Mutations in two receptors of the transforming growth factor-beta family have recently been
shown to be present in the majority of cases of inherited (familial) pulmonary arterial
hypertension (PAH). Study of the biology of these receptors, bone morphogenetic protein
receptor type-2 (BMPR2), and activin-like kinase type-1 (ALK-1) will certainly reveal
pathogenic mechanisms of disease. Exonic mutations in BMPR2 are found in about 50% of
patients with familial PAH, and ALK1 mutations are found in a minority of patients with
hereditary hemorrhagic telangiectasia and co-existent PAH. Because familial PAH is highly
linked to chromosome 2q33, it is likely that the remaining 50% of family cases without exonic
mutations have either intronic BMPR2 abnormalities or alterations in the promoter or
regulatory genes. Also, only about 10% of patients with “sporadic” idiopathic PAH have
identifiable BMPR2 mutations. Mutations in BMPR2 confer a 15% to 20% chance of
developing PAH in a carrier’s lifetime. Thus, there must be gene-gene or gene-environment
interactions that either enhance or prevent the development of the vascular disease in persons
carrying a mutation, and there must be other patterns of susceptibility based on genetic
makeup. To elucidate the genetic basis of PAH further, investigations are needed, including
genome scanning for major and minor genes, analysis of genetic profiles of patients for
candidate genes likely to modify risk for disease (e.g., serotonin transporter alleles, nitric
oxide-synthases), proteomics, transgenic mice, and altered signal transduction. Advances in
genetic testing, presymptomatic screening, and biomarkers should permit early detection of
disease in those at risk of PAH and allow trials of preventive therapy in carriers. (J Am Coll
Cardiol 2004;43:33S–39S) © 2004 by the American College of Cardiology Foundationr
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nn this report, the state of knowledge with regard to the genetic
asis of pulmonary arterial hypertension (PAH) will be sum-
arized, and future approaches will be outlined. The genetic
asis of all forms of PAH is broader than that for the disease
raditionally called “familial primary pulmonary hypertension”;
ultiple genetic conditions associated with pulmonary hyper-
ension are listed in Table 1. This report will be largely
onfined to the genetic basis of forms of PAH related to
utations in bone morphogenetic protein receptor type-2
BMPR2) and activin-like kinase type-1 (ALK1), two recep-
ors in the transforming growth factor (TGF)-beta family.
A familial association with primary pulmonary hyperten-
ion (PPH, now termed idiopathic PAH) was reported by
resdale in 1954 (1) only three years after the first descrip-
ion of this disease (2). Subsequent case reports of other
amilies with two or more members affected with PAH were
ade in American and European published data, and in
984 contact was made with 13 previously reported families,
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edicine, Salt Lake City, Utah.aManuscript received December 16, 2003; accepted February 3, 2004.evealing numerous new cases in close and distant relatives
3). The pattern of inheritance was observed to be autoso-
al dominant with highly variable and incomplete expres-
ion among families, a female predominance, the suggestion
f genetic anticipation, and a clinical course indistinguish-
ble from nonfamilial PAH (4). In the National Institutes
f Health (NIH)-funded PPH (PAH) registry, 6% of
ffected patients were identified as having familial disease
5).
The development of family registries and banking of
eoxyribonucleic acid led to linkage studies using microsat-
llite markers that localized a marker for familial PAH on
hromosome 2q31-32 (6,7). The possibility of other in-
olved loci has not been systematically examined, although
ll families studied link disease to that region of chromo-
ome 2 (8). Because the segment on chromosome 2 was too
ong for easy sequencing, a candidate gene approach led to
he identification of mutations in a receptor in the TGF-
eta superfamily of receptors, BMPR2, in association with
isease (9,10). The strategy employed to identify the
isease-causing gene is summarized in Figure 1.
Recently, a second PAH gene was found in some persons
ith hereditary hemorrhagic telangiectasia (HHT) whose
utation in ALK1 receptor confers susceptibility to pulmo-
ary hypertension in addition to HHT lesions (11). This
ppears to be a less common cause of heritable PAH,
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Genetic Basis of Pulmonary Hypertension June 16, 2004:33S–39Slthough as a member of the TGF-beta family, ALK1 is
ikely to share signaling abnormalities with mutated
MPR2 (12,13).
HE BMPR2 MUTATIONS IN FAMILIAL PAH (PPH)
he BMPR2 gene, on chromosome 2q33, has 13 exons.
xons 1–3 encode an extracellular domain, exon 4 encodes
he transmembrane domain, exons 5–11 a serine/threonine
inase domain, and exons 12 and 13 a very large intracellular
-terminus of unknown function that appears to be unique
o BMPR2. Mutations in familial PPH have been reported
n all exons except for 5 and 13 (9,10). Polymorphisms have
een found in exons 6, 8, and 12. Each mutation is unique
Abbreviations and Acronyms
ALK1  activin-like kinase type-1
BMPR2  bone morphogenetic protein receptor type-2
HHT  hereditary hemorrhagic telangiectasia
PAH  pulmonary arterial hypertension
PASP  pulmonary artery systolic pressure
PPH  primary pulmonary hypertension (now termed
idiopathic PAH)
TGF  transforming growth factor
able 1. PAH: Mendelian Causes
. Idiopathic PAH: PPH
1. Exonic mutations in BMPR2 (50% of known families with familial
PPH)
2. Intronic mutations in BMPR2 (up to 15% of families currently
identified)
3. Isolated exonic BMPR2 germline mutations (about 10% of sporadic
cases)
a. Spontaneous heritable mutation
b. Inherited mutation in a family with no other clinically affected
individuals
4. ALK1 mutations associated with hereditary hemorrhagic
telangiectasia (rare)
5. Other PPH mutations near region q32 on chromosome 2, as yet
unidentified?
6. Other Mendelian PPH genes in the genome? (unlikely but
uncertain)
. Pulmonary veno-occlusive disease
1. One family identified with a BMPR2 exonic mutation. Screening
of isolated cases underway (likely to be a rare association).
. Sickle cell anemia
1. SS and SC hemoglobinopathies leading to repeated pulmonary
vascular injury and pulmonary vascular thrombosis
. Gaucher’s disease
1. It is currently unclear what the genetic relationship is. Some
Gaucher disease patients have had splenectomies, and BMPR2
polymorphisms have been found in four; significance as yet
unknown.
. Conditions where major genes are likely to be associated with PAH
1. Hypercoagulable states, including PAI-1 inhibitor mutations
2. High-altitude pulmonary edema, disorders of ventilatory drives,
hypoxic pulmonary hypertension
3. Collagen vascular diseases.
LK1  activin-like kinase type-1; BMPR2  bone morphogenetic protein receptor
ype-2; PAH  pulmonary arterial hypertension; PAI  plasminogen activatorcnhibitor; PPH  primary pulmonary hypertension.o a family and co-segregates with disease. The amino acid
ubstitutions resulting from point mutations are in either
ighly conserved or functionally critical domains of the
eceptor, and thus are predicted to alter receptor function
14–16). The TGF-beta family of receptors is highly
onserved throughout nature. Other missense mutations
redict truncation of coding of the transcript. The location
f the mutation in families with BMPR2-related PPH does
ot seem to alter the gender ratio, age of onset, or severity
f disease. Locations of many of the known mutations in
MPR2 are shown in Figure 2. A mutation in BMPR2 was
ecently reported in a family with pulmonary hypertension
ue to veno-occlusive disease, suggesting that the signaling
bnormality is not confined to the precapillary arterioles in
ll cases (17).
HE BMPR2 MUTATIONS IN “SPORADIC” PAH
bout 25% of sporadic cases of PPH were initially thought to
ave BMPR2 mutations (18), although more recent unpub-
ished analyses of sporadic cases by multiple groups have placed
his closer to 10%. Semantic confusion arises when an appar-
ntly sporadic case of PPH is found to have an exonic BMPR2
utation. In some cases, this is apparently a new spontaneous
ermline mutation, which presumably can be inherited by any
ffspring and carries the same 15% to 20% risk of disease. In
ther cases, the mutation has been found to be inherited, and
hus is really a family case, albeit the first diagnosis in the
amily. The rate of mutations in the general population is
nknown, but must be exceedingly low because of their
bsence in control populations. Of the remaining cases of
pparently sporadic PPH, about 90%, a small number might
ave intronic BMPR2 mutations, ALK1, or other Mendelian
auses, but the majority do not appear to have a major genetic
asis for disease. It is likely that genetic predispositions exist
ased on normal variations in genes that may influence the
ulmonary circulation (Table 2).
HE BMPR2 MUTATIONS IN OTHER COHORTS
he population carrier frequency for BMPR2 mutations has
ot been measured. However, an indirect estimate suggests
hat it is as low as 0.001% and may be as high as 0.01% (19).
n data concerning normal control cohorts already published,
mounting to about 350 subjects (9,10,14,19), no exonic
MPR2 mutations have been found that would be predicted
o alter function of the receptor.
AH with appetite-suppressant drugs. Mutations of the
MPR2 gene have been reported in PAH associated with
enfluramine derivatives (19). Three BMPR2 mutations
ere found in 33 unrelated French patients (9%), and a
ourth mutation in two sisters. The three single mutations
ere exon 2 A246C, exon 5 G545A, and exon 11 T1447C,
ll predicted to reduce function of the receptor. The two
isters had an exon 6 631C T mutation, resulting in a
onsense mutation (R211X) predicted to produce a trun-
ated protein. The mutation-positive patients had a some-
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June 16, 2004:33S–39S Genetic Basis of Pulmonary Hypertensionhat shorter duration of fenfluramine exposure before
llness than did the mutation-negative patients. The import
f this data is compatible with the working hypothesis that
ene-gene or gene-environmental interactions are required
or the onset of PPH.
AH with scleroderma-spectrum disease. Germline het-
rogeneous BMPR2 mutations were not found in 24 pa-
ients with PAH in the scleroderma spectrum of disease
20). However, one centromere-positive Jewish patient with
ocalized cutaneous CREST had an exon 13 G2948A
R983Q) variant considered likely to be a polymorphism
ecause the same mutation was also found in one of 100
ormal Israeli Ashkenazi Jews. This polymorphism has not
een found in 350 normal chromosomes. Another report
ailed to find BMPR2 mutations in 12 patients with PAH
nd connective tissue diseases (21).
uman immunodeficiency virus (HIV)-associated
AH. PORTAL HYPERTENSION AND CONGENITAL HEART
ISEASE. No BMPR2 mutations were found in 19 French
igure 1. The process leading to the discovery of mutations in bone mor
ulmonary hypertension is depicted. Collection of deoxyribonucleic acid fro
inkage studies using microsatellite markers that led to identification of a ch
he Human Genome Project (HGP) in the interval were then identified a
MPR2 gene were found that co-segregated with affected individuals knoatients with HIV-associated PAH, 11 intravenous drug abuse, and 8 via sexual/blood contact (22). No BMPR2
utations were found in 11 similar U.S. patients and 25
ritish patients (J. A. Morse and R. C. Trembath, unpub-
ished data, June 2003). There have been no published
eports of BMPR2 mutations in adults and children with
AH and congenital systemic-to-pulmonary shunts and in
ortopulmonary PAH.
mmunogenetic studies of PAH. There are few immuno-
enetic studies of PPH despite earlier reports of antinuclear
ntibodies in this disease. Previous immunogenetic studies
f PPH have reported antibody/HLA-DR, -DQ correla-
ions in small subsets of patients (23). Anti-fibrillin-1
utoantibodies were the only ones found in high frequency;
0 of 75 adults with PPH (93%), 28 of 33 children with
PH (85%), and 12 of 18 with fenfluramine-associated
AH (67%) (22), but no significant HLA-class II associa-
ions were discovered.
A recent study of three U.S. ethnic groups with (sclero-
erma spectrum of disease), Hispanics, African Americans,
netic protein receptor type-2 (BMPR2) as the cause of familial primary
milies with sufficient numbers of affected and unaffected members allowed
some interval on chromosome 2, at q31–32. Candidate genes known from
ted by deoxyribonucleic acid sequencing. Point mutations in exons of the
rom the family pedigrees.phoge
m fa
romo
nd tes
wn fnd Caucasians, found African Americans more likely to
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Genetic Basis of Pulmonary Hypertension June 16, 2004:33S–39Save diffuse skin involvement and pulmonary hypertension
24). Caucasians had more anticentromere antibodies and
frican Americans more anti-U1-ribonucleoprotein and
nti-fibrillarin (U3-RNP) antibodies. Of interest, HLA-
QB1*0301 (DQ7) was also increased in sporadic PPH
ith tissue plasminogen activator antibodies. Autoantibod-
es against B23, a nucleolar phosphoprotein, were associated
ith systemic sclerosis and PAH (25). Also, B23 positivity
as related to anti-fibrillarin antibodies, anti-RNP antibod-
es, and decreased lung capacity, but HLA alleles were not
ssessed. An Italian group found anti-topoisomerase II
ntibodies in SSc with pulmonary hypertension and HLA-
35, but no HLA-class II associations (26). This same
roup also correlated the menopause with HLA-B35 as a
igure 2. Shown from left to right are exons 1–3 in the extracellula
orphogenetic protein or other transforming growth factor-beta ligand. Ex
hosphorylates SMAD proteins. The cytoplasmic tail (exons 12-13) is an
re frameshift or nonsense changes that predict truncation of the gene tra
able 2. Partial List of Candidate Genes That May Modify the
isk for PAH
itric oxide synthases (1 and 3)
asoactive intestinal polypeptide
erotonin transporter (SERT alleles)
rea cycle enzymes—pathway to arginine and nitric oxide
rostacyclin receptor
eta-adrenergic receptors
oagulation cascade polymorphisms (in addition to PAI-1, platelet
glycoproteins, others)
mmunogenetic background related to HLA and immune processing
omatic mutations in BMPR1
otassium channel disorders
MPR1  bone morphogenetic protein receptor type-1; HCA  histocompatibility
ocus antigen; PAH pulmonary arterial hypertension; PAI plasminogen activator(nhibitor.isk factor for isolated pulmonary hypertension in SSc (27).
t is hoped that future studies will provide the patient
umbers and immunogenetic associations using the re-
uired careful ethnic matching of patient cohorts to
ontrols.
CREENING OF ASYMPTOMATIC
ARRIERS OF IDIOPATHIC PAH (PPH) GENES
n PPH, symptoms almost never develop until there is
dvanced obstruction of the vascular bed with extreme
ulmonary hypertension and right heart dysfunction (28). It
s hoped that earlier diagnosis and treatment of this disease
ay lead to better outcomes.
One recent approach to early diagnosis is the identifica-
ion of gene carriers in families with heritable PPH by
easurement of pulmonary arterial pressure at rest and
uring exercise (29). These studies suggest that 95% of
amily members who possess the risk haplotype or the
MPR2 mutation have an abnormal pulmonary artery
ystolic pressure (PASP) response to exercise (29,30). Most
utation carriers in the study were asymptomatic and had
ormal pulmonary vascular resistance and pulmonary artery
ressures at rest and normal right heart measurements and
unction. In most subjects carrying the risk haplotype or the
MPR2 mutation, an abnormal increase of PASP (range,
1 to 80 mm Hg) occurred during exercise at low workloads
ain, involved in dimerization with BMPR1 upon activation by bone
pans the transmembrane, and exons 5-11 represent the kinase domain that
ual feature of transforming growth factor-beta receptors. Most mutations
t. PPH  primary pulmonary hypertension.r dom
on 4 s
unus50 to 125 W). These pressures equaled or exceeded systolic
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June 16, 2004:33S–39S Genetic Basis of Pulmonary Hypertensionressures achieved with extreme exercise (240 W) in athletes
31).
Measurement of PASP using Doppler echocardiography
uring supine bicycle exercise might be useful to reveal
enetic susceptibility to the disease. In a preliminary
ollow-up of 28 PPH-gene carriers, one subject with an
bnormal response to exercise manifested PPH within three
ears. Screening by echocardiography has also resulted in
he identification of PPH in several asymptomatic family
embers (32). Furthermore, only a small portion of asymp-
omatic abnormal responders will develop overt disease, and
redictive biomarkers have not yet been defined.
Pulmonary systolic pressure during exercise may rise to
igh levels in some normal individuals, potentially leading
o a false positive diagnosis. In addition, left ventricular
lling dysfunction may lead to reactive pulmonary hyper-
ension and the false diagnosis of PAH. To elucidate these
mportant issues, a prospective, controlled European Union
roject to evaluate Doppler echocardiography during exer-
ise and hypoxic challenge in PAH families and in control
ubjects has been started.
ENETIC TESTING AND COUNSELING
he value of a genetic test to estimate an individual’s risk for
eritable disease depends on the risks and benefits of such
nowledge (33). In some diseases where the penetrance is
igh and preventive treatment is available (e.g., multiple
ndocrine neoplasia), the benefits of gene testing far out-
eigh the risks (34). Conversely, when no effective inter-
ention is available (e.g., Huntington’s disease), the risk of
enetic certainty may exceed the benefit of knowing the
nswer. In all genetic diseases, both pretest and posttest
enetic counseling are essential for best care of subjects (35).
urrent understanding and the state of clinical testing in
amilial PPH. The gene that codes for the BMPR2 recep-
or is large (13 exons); presently, screening for mutations is
onfined to persons with a known positive family history.
ven in this circumstance, the sensitivity of testing for
MPR2 mutations is limited, because at least 50% of
amilies studied to date do not have exonic mutations in
MPR2. Haplotype testing can be performed if a large
nough group of affected and unaffected members of a
amily are available. However, tests for known BMPR2
utations can be performed at a reasonable cost with high
ensitivity and specificity. One problem is that each family
as a unique mutation. The penetrance of disease for all
nown BMPR2 mutations is variable, as low as 15% to 20%
n most families, but as high as 80% in some family groups
36). Therefore a deoxyribonucleic acid-based test for
nown BMPR2 mutations identifies increased risk to de-
elop PPH but not necessarily the disease itself. Genetic
esting is simply not ready for broad implementation in
diopathic PAH, but is appropriate in screening programs in
amilies where the mutation is known and counseling is
vailable.Federally certified clinical laboratories are required by law
o assure accuracy of results and avoidance of errors such as
ontamination of specimens. Genetic testing and counseling
ust be done solely for the benefit of the person tested.
ssues of family planning, family relationships, work envi-
onment, self-image, insurability, and social comfort can
nly be sorted by careful personal counseling by an informed
nd experienced genetic counselor.
reliminary study of attitudes and understanding in
amilial PPH. A first step in measuring and understanding
he psychosocial implications of familial PPH was explored
efore BMPR2 was identified in association with PPH (37).
ighty-two members of a family cohort (75%) agreed to
ake part, and 62 completed a phone interview. More than
6% of respondents stated that they probably or definitely
ould have genetic testing if it became available. There was
greater interest in testing if a definite answer could be
rovided (p  0.001). The most important reason for
anting testing done was to learn about the risk to their
hildren. Reasons given for not wanting testing included
oncern about the effects on family, ability to handle the
esults emotionally, and concern about insurance and insur-
bility (although this factor was less prominent than in other
tudies). Nearly 20% of the respondents appeared to be
onfused about the difference between diagnostic testing
nd the donation of blood for research studies (37).
Numerous investigations have revealed that the expressed
nterest in predictive genetic testing often exceeds actual
ptake. In Huntington’s disease, more than 80% of people
t risk expressed interest in testing, but only 10% of these
ndividuals have chosen testing since the gene was identified
38). Factors affecting a person’s decisions about testing
ary, and include gender (women are more likely to be
ested), perceived risk, desire to decrease uncertainty, avail-
bility of effective and acceptable medical interventions,
oncern about one’s current and future children, and the
resence of symptoms of depression (39).
ENETIC MODIFICATION OF
HE RISK FOR ACQUIRING PPH
able 2 lists some known and potential genetic modifiers of
he risk for development of PAH. The list is necessarily
mcomplete, and the relative importance of each or any of
hese genes is unknown. There may be groupings of
olymorphisms that confer risk for PAH, especially if there
re environmental stresses (such as fenfluramine or splenec-
omy). The analysis of associations of genes with the risk for
isease is a complex statistical problem. Pulmonary arterial
ypertension is a complex genetic disease, and the interac-
ion of underlying major genes (such as BMPR2) and
odifying genes coupled with environmental stresses will be
he focus of future investigations. In addition to statistical
ssociations, functional studies will be necessary to confirm
hat an associated gene product actually modifies risk.The serotonin transporter is the gene and product repre-
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Genetic Basis of Pulmonary Hypertension June 16, 2004:33S–39Senting the best-studied modifier of pulmonary hypertensive
tates. Cultured pulmonary artery-smooth muscle cells from
atients with PPH have an abnormally strong proliferative
esponse to serotonin or serum (40). This abnormal re-
ponse is due to overexpression of the serotonin transporter
5-HTT), owing in part to a functional polymorphism
ocated on the 5-HTT gene promoter: homozygosity for the
L) allele, the long gene promoter variant associated with a
igh level of gene transcription, is found in 65% to 75% of
atients with PPH as compared to 25% to 30% of controls
41). Recent results showing that 5-HTT gene polymor-
hism determines the severity of pulmonary hypertension
PH) in hypoxemic patients with chronic obstructive lung
isease support a major role for LL-genotype–driven
-HTT overexpression in the pathophysiology of various
orms of PH. Thus, 5-HTT gene polymorphism may be
ither an important modifier of the PH phenotype or a
actor conveying susceptibility to PH in some individuals
42).
ransgenic models of PAH. Several groups are studying
ouse models that carry BMPR2 mutations. The first of
hese, developed by Beppu et al. (43), is a true null. Mice
hat are homozygous for this mutant BMPR2 die very early
n development during gastrulation. Delot et al. (44) have
lso developed a mouse that carries an in-frame deletion of
xon 2 resulting in loss of the ligand binding portion of the
xtracellular domain. Mice homozygous for the hypomor-
hic allele also die in utero, but not until day 12.5.
athologic analyses of these mice have shown persistence of
he truncous arteriosus of the heart, demonstrating the
mportance of functioning BMPR-II for normal heart
evelopment.
Recently, Beppu et al. (43) have reported analyses of mice
hat carry the null BMPR2 allele in the heterozygous state.
hough these mice did not spontaneously develop PH, after
hree weeks of chronic hypoxia, both pulmonary vascular
esistance and right ventricle/left ventricle  septum were
reater in the heterozygous mice than in the homozygous
ild-type mice. Overexpression of 5-lipoxygenase (5-LO)
n the lungs of the BMPR2 null heterozygous mice using a
eplication-deficient adenovirus led to an increase in PA
ressure as compared to homozygous wild-type mice. Thus,
-LO may modify the susceptibility of BMPR2 null het-
rozygous mice to the development of PPH.
Genetic manipulation of the laboratory mouse has be-
ome a very powerful tool for the study of human disease.
imple transgenics and knockouts can potentially be useful
or the “quick” determination as to whether a specific gene,
hen overexpressed or downregulated, can play a role in the
usceptibility to the development of PH. The transgenic and
nockout models can be crossed to produce mice carrying
utations in more than one gene to examine the synergistic
ffects of certain combinations of mutations to determine
odifier gene effects. Unfortunately, tissue specificity may
lay an important role in development of the disease, and
hese studies will then require animal models for which genexpression in specific tissues can be switched on and off. The
ransgenic approach to the study of PPH is clearly in its
nfancy. There are many mouse models yet to be generated,
nd only time will tell as to their usefulness for the
nraveling of the pathogenesis of the disorder.
ummary. Future studies will focus on the search for
odifiers, both environmental and genetic, that determine
he initiation and perpetuation of the disease in individuals
arboring mutations in genes conferring increased risk for
his devastating condition. These studies will benefit from
ecent technological advances that enable tissue and cell-
pecific profiles of both the deoxyribonucleic acid transcript
nd the proteomic product together with the generation of
argeted animal models of the disease. The search for and
ubsequent investigation of potential modifier genes will
equire assessment in patient and family cohorts sufficiently
owered to generate statistically robust outcomes. Studies of
he functional consequences of such mutations on cellular
ignaling will be necessary to understand the biology of
isease. Recent advances have established the need to
evelop protocols for presymptomatic screening of at-risk
amily members as a prelude to the initiation of clinical trials
f preventive therapy. Therapy aimed at either prevention or
ctual reversal of the vascular disease process will be the
ltimate goal for the betterment of these patients and their
amilies.
eprint requests and correspondence: Dr. John H. Newman,
ivision of Pulmonary and Critical Care Medicine, T 1219
anderbilt University Medical Center North, Nashville, Tennes-
ee 37220-2650. E-mail: John.Newman@med.va.gov.
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